| Literature DB >> 34110591 |
Wendee M Wechsberg1,2,3,4, Felicia A Browne5,6, Courtney Peasant Bonner5,6, Yukiko Washio5, Brittni N Howard5, Isa van der Drift5.
Abstract
PURPOSE OF REVIEW: Alcohol is the most misused substance in the world. For people living with HIV (PLWH), alcohol misuse may impact ART adherence and viral suppression. This review of the most recently published alcohol intervention studies with PLWH examines how these studies considered gender in the samples, design, and analyses. RECENTEntities:
Keywords: ART adherence; Alcohol misuse; Gender; Viral suppression; Women living with HIV
Year: 2021 PMID: 34110591 PMCID: PMC8190977 DOI: 10.1007/s11904-021-00558-x
Source DB: PubMed Journal: Curr HIV/AIDS Rep ISSN: 1548-3568 Impact factor: 5.071
Fig. 1Search diagram
Interventions with people living with HIV who use alcohol (non-gender element)
| Citation | Population/country | Study arms | Alcohol use outcome measures | Viral load outcome measures | Findings |
|---|---|---|---|---|---|
| Edelman et al., 2019a [ | • Percentage of days abstinent (TLFB) • PEth blood levels (DBS) • Past 30-day abstinence (TLFB) • Drinks per week (TLFB) • Percentage of participants with no heavy drinking days (men: >5 drinks/day; women: >4 drinks/day; TLFB) • Mean number of drinks per drinking day (TLFB) | • Undetectable plasma HIV viral load (HIV RNA <50 copies/ml) | • At 24- and 52-week follow-up: Both study arms reported increased alcohol abstinence; No significant differences in alcohol use or viral load outcomes between study arms | ||
| Edelman et al., 2019b [ | • At 24- and 52-week follow-up: Both study arms reported increased alcohol abstinence; No significant differences in alcohol use or viral load outcomes between study arms | ||||
| Edelman et al., 2020 [ | • At 24- and 52-week follow-up: Both study arms reported increased alcohol abstinence; No significant differences in alcohol use or viral load outcomes between study arms | ||||
| Go et al., 2020 [ | • Self-reported percentage of days abstinent (TLFB) • Number of drinks per day (TLFB) • Heavy drinking days (defined as >4 drinks for men and >3 drinks for women; TLFB) | • Viral suppression (HIV RNA <20 copies/ml) | • At 3-, 6-, and 12-month follow-up, participants in • Participants in the Brief Alcohol Intervention arm were more likely to be virally suppressed than participants in the SOC arm (89.2% vs. 78.1%) at 12-month follow-up • At 3- and 6-month follow-up, participants in | ||
| Madhombiro et al., 2020 [ | • AUDIT score | • Adherence (percentage of scheduled visits for medication refills in the past 3 months) • Viral suppression (<40 copies/ml) • CD4 count | • • Both study groups had a significant decrease in viral load, but no statistically significant difference between the study arms at 6-month follow-up • No statistically significant reduction in CD4 count within groups and/or between study arms at 6-month follow-up | ||
| Stein et al., 2020 [ | • Drinking days (TLFB) • Number of drinks per day (TLFB) • Addiction Severity Index | • HIV RNA viral load | • Drinks per drinking day significantly reduced in both study groups, but reductions were not statistically significant between study groups • No statistically significant treatment effects for any alcohol use outcome • No HIV outcomes reported | ||
| Satre et al., 2019 [ | • Number of drinking days in the past 30 days • Addiction Severity Index • Alcohol Importance Ruler, and Confidence Ruler | • Self-reported ART adherence • HIV RNA levels | • All arms demonstrated a statistically significant decrease in alcohol use outcomes, but no significant difference between arms • Among participants who reported that reducing drinking was of low importance ( | ||
| Naar et al., 2020 [ | • Severity of problems (ASSIST) • Number of drinks per week (TLFB) | • Undetectable plasma HIV viral load (HIV RNA <20) | • Participants in the clinic delivery group maintained reductions in alcohol • The clinic delivery group had |
Note: ART, antiretroviral therapy; ASSIST, Alcohol Smoking and Substance Involvement Screening Test; AUD, alcohol use disorder; AUDIT-C, Alcohol Use Disorders Identification Test-Consumption; DBS, dried blood spot; HBV, hepatitis B virus; HCV, hepatitis C virus; ISAT, Integrated Stepped Alcohol Treatment; NIH, National Institutes of Health; MICBT, Motivational Interviewing + brief Cognitive Behavioral Therapy; PEth, phosphatidylethanol; RNA, ribonucleic acid; SOC, standard of care; STI, sexually transmitted infection; TB, tuberculosis; TLFB, Timeline Followback; WHO, World Health Organization
Bold font in the Findings column indicate statistically significant differences between arms
Interventions with people living with HIV who use alcohol (gender element)
| Citation | Population/setting | Study arms | Alcohol use outcome measures | Viral load outcome measures | Findings |
|---|---|---|---|---|---|
| Cook et al., 2019 [ | • The average number of drinks per week (TLFB) • Number of days of abstinence (TLFB) • Number of binge-drinking days in the past 30 days (TLFB) • PEth blood levels (DBS) | • Self-reported ART adherence • CD4+ cell count • Undetectable plasma HIV viral load (HIV RNA <200 copies/ml) | • • No significant difference in odds of reducing or quitting drinking or other alcohol outcomes between study arms at follow-points • Adherence and viral load outcomes did not differ by group | ||
| Huis in’t Veld et al., 2019 [ | • 10-item AUDIT | • CD4+ count; viral load • ART adherence | • Intervention and counseling session participants have a significant reduction in AUDIT scores; no significant difference between study groups • Intervention participants’ mean last measured CD4 count was significantly lower at time point 1 but not at time point 2 • Intervention did not influence other HIV outcomes | ||
| Papas et al., 2021 [ | • Percentage of drinking days (TLFB) • Drinks per drinking day (TLFB) • Asking participants how much money they spent on personal consumption | • Self-reported ARV adherence • HIV RNA concentration (<40 copies/ml) | • • Adherence and competence scores in both CBT and HL conditions did not differ significantly by gender | ||
| Wechsberg et al., 2019 [ | • Average number of drinks per day | • Undetectable viral load (<1360 copies/ml) for subsample | • Among the subsample with viral load data, the WHC+ arm was statistically significantly more likely to have a nondetectable viral load ( • | ||
| Wechsberg et al., 2021 [ | WHC implemented in health and substance use clinics over 4-cycles via a modified stepped- wedge design implementation science trial | • Alcohol use (self-reported frequency, amount, binge drinking to calculate heavy alcohol use [4 or more drinks on any given day, and 7 or more drinks per week]) | • ART initiation and adherence • Awareness of CD4 count | • Compared with cycle 1, women in cycle 4 were • Compared with women in cycle 1, women in cycle 4 were • Likelihood of taking ART increases as women are enrolled in the later cycles and the risk of AUD decreases • WHC increased ART adherence and reduced alcohol use |
Note: ART, antiretroviral therapy; AUD, alcohol use disorder; AUDIT, Alcohol Use Disorders Identification Test; CBT, cognitive behavioral therapy; DBS, dried blood spot; PEth, phosphatidylethanol; STI, sexually transmitted infection; TB, tuberculosis; TLFB, Timeline Followback
Bold font in the Findings column indicate statistically significant differences between arms
Protocols
| Citation | Planned population/setting | Study arms | Proposed alcohol outcomes | Proposed HIV and viral load outcomes | Proposed findings |
|---|---|---|---|---|---|
| DiClemente et al., 2021 [ | • PEth levels (8 ng/ml) • EtG levels (500 ng/ml) | • HIV viral load (copies/ml) • CD4+ cell count | • To determine if a computer-based intervention that could provide better patient confidentiality and increased accessibility is efficacious in improving alcohol and HIV/HCV outcomes | ||
| Kane et al., 2020 [ | • 10-item AUDIT • ASSIST substance use measurement | • No proposed adherence or viral load outcomes | • Will reveal the effectiveness of an intervention addressing substance use and other comorbidities in an HIV clinic setting in sub-Saharan Africa | ||
| Magidson et al., 2020 [ | Hybrid Type 1 effectiveness implementation trial | • Urinalysis and self-report • WHO ASSIST | • ART adherence measured through Wisepill • Viral load (copies/ml) | • Determine whether this evidence-based intervention can be integrated into HIV care settings, considering workforce shortage in South Africa • Establish whether this intervention successfully addresses both HIV treatment and substance use |
Note: ASSIST, Alcohol Smoking and Substance Involvement Screening Test; AUDIT, Alcohol Use Disorders Identification Test; CBT, cognitive behavioral therapy; CETA, common elements treatment approach; EtG, ethyl glucuronide; HCV, hepatitis C virus; PEth, phosphatidylethanol; WHO, World Health Organization